Details

Last Funding Type

Series A

Last Funding Money Raised

$79.37M

Industries

Biopharma,Biotechnology,Health Care,Pharmaceutical

Founded date

Jan 1, 2019

Number Of Employee

11 - 50

Operating Status

Active

ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases.

ValenzaBio implements biomarker-driven approaches to guide research and clinical development. Our pipeline includes several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells. Our most advanced program has generated Phase 1 proof-of-concept in patients and we’re progressing preclinical programs focused on differentiated mechanisms of action. Our mission is to provide safe and effective treatment options for patients with unmet needs.